Company Analysis
Sign in

Context Therapeutics Inc. (CNTX)

Nasdaq: CNTX · Pharmaceutical Preparations · Philadelphia, PA · filing with the SEC since 2021
Full chart Alerts Compare
Grade5.5
◀ Past 3.9● Present 5.3▶ Future 6.6
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Income statement, as filed

In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.
Income statement, by fiscal year, newest first
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period endingDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020
Report filedMar 23, 2026Mar 20, 2025Mar 21, 2024Mar 22, 2023Mar 23, 2022·
For lenders
Net interest income··1,163,975547,268-64,240·
Research and development31,856,25222,701,33517,782,7317,091,1633,805,0671,641,501
General and administrative7,846,3797,222,5657,289,8857,790,0403,632,920930,667
Operating income-39,702,631-29,923,900-25,072,616-15,381,203-10,525,819-2,572,168
Interest expense····64,240661,224
Interest and investment income3,378,5453,200,2241,163,975···
Other income (expense), net200,471-1,428-55,570···
Total non-operating income (expense)··-55,570-2,004123,8720
Income tax expense000000
Net income-36,123,615-26,725,104-23,964,211-14,835,939-10,456,8706,644,465
Net income to common shareholders····-10,456,8701,070,907
Earnings per share, basic-0.38-0.46-1.50-0.93-3.693.07
Earnings per share, diluted-0.38-0.46-1.50-0.93-3.69-3.96
Weighted average shares, basic95,185,68358,416,14115,966,05315,966,0532,833,674348,368
Weighted average shares, diluted95,185,68358,416,14115,966,05315,966,0532,833,6742,054,875
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Net interest income interest earned less interest paidus-gaap:InterestIncomeExpenseNet
Research and development spent on inventing what it sells nextus-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
General and administrative the cost of running the company itselfus-gaap:GeneralAndAdministrativeExpense
Operating income profit from running the business, before interest and taxus-gaap:OperatingIncomeLoss
Interest expense what its borrowing costus-gaap:InterestExpense
Interest and investment income what its cash and investments earnedus-gaap:InvestmentIncomeInterest
Other income (expense), net gains and costs outside the businessus-gaap:OtherNonoperatingIncomeExpense
Total non-operating income (expense) everything outside the business, togetherus-gaap:NonoperatingIncomeExpense
Income tax expense tax charged on the period's profitus-gaap:IncomeTaxExpenseBenefit
Net income the profit or loss that belongs to the company's shareholdersus-gaap:NetIncomeLoss
Net income to common shareholders what is left for common shareholdersus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Earnings per share, basic net income per share outstandingus-gaap:EarningsPerShareBasic
Earnings per share, diluted net income per share, counting every share that could be issuedus-gaap:EarningsPerShareDiluted
Weighted average shares, basic the average count of shares outstandingus-gaap:WeightedAverageNumberOfSharesOutstandingBasic
Weighted average shares, diluted the average count with every share that could be issuedus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
SI Assistanton CNTX · research, not advice